Back to Authors

Stephani, Ulrich

https://orcid.org/0000-0003-0493-7522

A5041942422 | I32021983

Mayo Clinic

Christian-Albrechts-Universität zu Kiel

Citations 2

Fenfluramine for Treatment-Resistant Seizures in Patients With Dravet Syndrome Receiving Stiripentol-Inclusive Regimens

JAMA Neurology | December 2, 2019 | Volume: 77 | Issue: 3 | Pages: 300

10.1001/jamaneurol.2019.4113 | PMID 31790543

Transition issues for benign epilepsy with centrotemporal spikes, nonlesional focal epilepsy in otherwise normal children, childhood absence epilepsy, and juvenile myoclonic epilepsy

Epilepsia | September 10, 2014 | Volume: 55 | Issue: s3 | Pages: 16-20

10.1111/epi.12706 | PMID 25209080

SummaryThis chapter covers the syndromes of benign epilepsy with centrotemporal spikes (BECTS), nonlesional focal epilepsy in otherwise normal children (NLFN), and the genetic generalized epilepsies. BECTS is an epilepsy syndrome that always enters terminal remission before the general age of a planned transition of adolescents. This is also the case for the majority (65%) of those with childhood absence epilepsy (CAE). Approximately 15% of patients with CAE who initially remit during their childhood years later develop juvenile myoclonic epilepsy (JME) as teenagers. They will have many issues for continuing medical care and transition, because their seizure disorder generally persists into adulthood. A significant minority of NLFN (~35%) and most patients with JME continue to have active epilepsy into adulthood. In addition, CAE, JME, and NLFN patients are at risk of a number of significant adverse social outcomes that require ongoing advice and counseling.